1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Eye conditions

Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion

Technology appraisal guidance [TA305] Published date: 26 February 2014

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
  • Overview
  • 1 Guidance
  • 2 The technology
  • 3 The manufacturer's submission
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Related NICE guidance
  • 7 Review of guidance
  • 8 Appraisal Committee members and NICE project team
  • 9 Sources of evidence considered by the Committee
  • About this guidance
  • Share
    • Share
    • Linked In
    • Twitter
    • Facebook
    • Email
    • More...
  • Download

Guidance

  • Next

6 Related NICE guidance

6 Related NICE guidance

Details are correct at the time of publication. Further information is available on the NICE website.

  • Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion. NICE technology appraisal guidance 283 (2013).

  • Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion. NICE technology appraisal guidance 229 (2011).

  • National Institute for Health and Care Excellence (NICE)

  • Next